Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Zaremba A, Chorti E, Jockenhöfer F, Bolz S, Sirin S, Glas M, Becker JC, Ugurel S, Roesch A, Schadendorf D, Livingstone E, Hagenacker T, Zimmer L.

J Immunother Cancer. 2019 May 29;7(1):141. doi: 10.1186/s40425-019-0626-9.

2.

The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients.

Saruwatari K, Sato R, Nakane S, Sakata S, Takamatsu K, Jodai T, Mito R, Horio Y, Saeki S, Tomita Y, Sakagami T.

Cancers (Basel). 2019 Jan 24;11(2). pii: E140. doi: 10.3390/cancers11020140.

3.

Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment.

Psimaras D, Velasco R, Birzu C, Tamburin S, Lustberg M, Bruna J, Argyriou AA.

J Peripher Nerv Syst. 2019 Aug 8. doi: 10.1111/jns.12339. [Epub ahead of print] Review.

PMID:
31393660
4.

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.

Makarious D, Horwood K, Coward JIG.

Eur J Cancer. 2017 Sep;82:128-136. doi: 10.1016/j.ejca.2017.05.041. Epub 2017 Jun 27. Review.

PMID:
28666240
5.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

6.

Myasthenia gravis induced by avelumab.

Yuen C, Fleming G, Meyers M, Soliven B, Rezania K.

Immunotherapy. 2019 Oct;11(14):1181-1185. doi: 10.2217/imt-2019-0106. Epub 2019 Aug 29.

PMID:
31462152
7.

Pembrolizumab-induced myasthenia gravis: A fatal case report.

March KL, Samarin MJ, Sodhi A, Owens RE.

J Oncol Pharm Pract. 2018 Mar;24(2):146-149. doi: 10.1177/1078155216687389. Epub 2017 Feb 1.

PMID:
28147928
8.

Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.

Lau KH, Kumar A, Yang IH, Nowak RJ.

Muscle Nerve. 2016 Jun;54(1):157-61. doi: 10.1002/mus.25141. Epub 2016 May 19.

PMID:
27065302
9.

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab.

Bloom BC, Augustyn A, Pezzi TA, Menon H, Mayo LL, Shah SJ, Schwartz DL, Chmura SJ, Johnson FM, Welsh JW, Chun SG.

Front Oncol. 2019 Apr 5;9:223. doi: 10.3389/fonc.2019.00223. eCollection 2019.

10.

Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Kao JC, Brickshawana A, Liewluck T.

Curr Neurol Neurosci Rep. 2018 Aug 4;18(10):63. doi: 10.1007/s11910-018-0878-7. Review.

PMID:
30078154
11.

PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review.

Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A, Viganò MG, Petrella G, Gianni L, Gregorc V.

Cancers (Basel). 2019 Mar 1;11(3). pii: E296. doi: 10.3390/cancers11030296. Review.

12.

Response to Anti-PD-1 Therapy in Metastatic Merkel Cell Carcinoma Metastatic to the Heart and Pancreas.

Mantripragada K, Birnbaum A.

Cureus. 2015 Dec 13;7(12):e403. doi: 10.7759/cureus.403.

13.

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma.

Werner JM, Schweinsberg V, Schroeter M, von Reutern B, Malter MP, Schlaak M, Fink GR, Mauch C, Galldiks N.

Front Oncol. 2019 Feb 14;9:84. doi: 10.3389/fonc.2019.00084. eCollection 2019.

14.

Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.

Samimi M.

Am J Clin Dermatol. 2019 Jun;20(3):391-407. doi: 10.1007/s40257-019-00427-9. Review.

PMID:
30784027
15.

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.

Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4.

PMID:
30528137
16.

Anti-PD-L1 Treatment Induced Central Diabetes Insipidus.

Zhao C, Tella SH, Del Rivero J, Kommalapati A, Ebenuwa I, Gulley J, Strauss J, Brownell I.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):365-369. doi: 10.1210/jc.2017-01905.

17.

The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.

Ma K, Lu Y, Jiang S, Tang J, Li X, Zhang Y.

Front Pharmacol. 2018 Dec 11;9:1430. doi: 10.3389/fphar.2018.01430. eCollection 2018. Review.

18.

[A case of myasthenia gravis and myositis induced by pembrolizumab].

Noda T, Kageyama H, Miura M, Tamura T, Ito H.

Rinsho Shinkeigaku. 2019 Aug 29;59(8):502-508. doi: 10.5692/clinicalneurol.cn-001251. Epub 2019 Jul 23. Japanese.

PMID:
31341124
19.

Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.

Gonzalez NL, Puwanant A, Lu A, Marks SM, Živković SA.

Neuromuscul Disord. 2017 Mar;27(3):266-268. doi: 10.1016/j.nmd.2017.01.002. Epub 2017 Jan 6. Review.

PMID:
28109638
20.

PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma.

Winkler JK, Bender C, Kratochwil C, Enk A, Hassel JC.

Br J Dermatol. 2017 Jan;176(1):216-219. doi: 10.1111/bjd.14632. Epub 2016 Oct 23.

PMID:
27038231

Supplemental Content

Support Center